hat
Doktè pafwa itilize finasteride pou tretman BPH, enfòmèlman konnen kòm yon pwostat elaji. Finasteride ka amelyore sentòm ki asosye avèk BPH tankou difikilte pou pipi, leve pandan lannwit lan pou pipi, ezitasyon nan kòmansman pipi, ak diminye koule urin. Li bay soulajman mwens sentòm pase alfabè alamè-1 tankou tamsulosin ak soulajman sentòm se pi dousman nan kòmansman (sis mwa oswa plis nan tretman ak finasteride ka oblije detèmine rezilta yo ka geri ou nan tretman). Benefisyè sentòm yo sitou wè nan moun ki gen volim pwostat&gt; 40 cm3. Nan etid alontèm finasteride, men se pa inibitè alfa-1 redwi risk pou reta egi egi (-57% nan 4 ane) ak bezwen pou operasyon (-54% nan 4 ane). Si yo sispann dwòg la, nenpòt ki benefis ki ka geri ou tounen nan 6-8 mwa.
eng
Physicians sometimes use finasteride for the treatment of BPH, informally known as an enlarged prostate. Finasteride may improve the symptoms associated with BPH such as difficulty urinating, getting up during the night to urinate, hesitation at the start of urination, and decreased urinary flow. It provides less symptomatic relief than alpha-1 blockers such as tamsulosin and symptomatic relief is slower in onset (six months or more of treatment with finasteride may be required to determine the therapeutic results of treatment). Symptomatic benefits are mainly seen in those with prostate volume &gt; 40 cm3. In long-term studies finasteride but not alpha-1 inhibitors reduce the risk of acute urinary retention (−57% at 4 years) and the need for surgery (−54% at 4 years). If the drug is discontinued, any therapeutic benefits reverse within about 6–8 months.